Facebook Instagram Pinterest Reddit Tumblr X Youtube
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 102

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for PTSD; Commits to Fund $20M Real-World Evidence Network

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke...

Psychedelic Neuroscience Demystified: How Psychedelics Alter Consciousness and Produce Therapeutic Effects

MIND CURE ANNOUNCES CLOSING OF LNG ENERGY’S SUBSCRIPTION RECEIPT FINANCING

Navigating Psychedelics: Jewish-Informed Perspectives on Psychedelics

PT429 – From Mycophobia to Fungi Fever: The Psychedelic Space’s Growing...

Natural Medicine Advisory Bulletin #2: July 2023

COMPASS Pathways Announces Second Quarter 2023 Financial Results and Business Highlights  

Across the Threshold: A Fireside on NDE’s with Psychedelics Today

Breathwork Explainer and Q+A

Psyence Group Announces SEC Registration Filing with NASDAQ SPAC, Newcourt, and Signing...

Load more

EDITOR PICKS

Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for...

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    Facebook Instagram Pinterest Reddit Tumblr X Youtube
    ©